ArticleCancer management and research2019
The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis.
Helei Hou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
36 papers cite it
this paperpooled itcites it